Back to Newsroom

Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology

BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sucampo AG (“SAG”), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”), announced today that it will present four posters evaluating the overall efficacy and tolerability of AMITIZA (lubiprostone) as a treatment for chronic idiopathic constipation (CIC).